According to the company, these patents are expected to “fuel the company’s rapid growth in the cosmetic industry” given consumer demand for products like sunscreen lotions and hair growth formulations.
Photo © Shutterstock.com/goodluz
Sabinsa Cosmetics, a division of Sabinsa Corp. (East Windsor, NJ), announced that it has received two patents for novel cosmetic compositions in the U.S. and Europe. The formulations are based on what the company says is extensive research on combinations of Sabinsa’s branded ingredients. According to the company these patents are expected to “fuel the company’s rapid growth in the cosmetic industry” given increasing consumer demand for products like sunscreen lotions and hair growth formulations.
The U.S. patent (US 9498423) is for a combination of Sabinsa’s β – glucogallin (1-O-galloyl-β-D-glucose) or β – glucogallin and total gallates from amla (Sabinsa’s branded Saberry ingredient), concentrate of liquid endosperm of Cocos nucifera (Sabinsa’s branded Cococin ingredient) and the selenopeptides (γ-L-glutamyl-Se-methyl-L-selenocysteine, and γ-L-glutamyl-L-selenomethionine) “for maintaining the morphology and numbers of the dermal papilla cells when exposed to stress signals.” Specifically, the formulation is said to protect the dermal papilla cells from stressors like UVB radiation, and maintain the number of live dermal papilla cells at a level of 95% or higher when they are exposed to UVB radiation. The company notes that this composition has also received patents in Europe (EP2695603), Japan (JP6064274), New Zealand (NZ600307) and Russia (RU2606752).
The European patent (EP2461786) is for a hair growth formulation comprising β – glucogallin (1-O-galloyl-β-D-glucose) from amla (Saberry) and a concentrate of liquid endosperm of Cocos nucifera (Cococin). In addition to promoting healthy hair growth, the company says this formulation has also been shown to protect dermal papilla cells from UV rays. The composition also previously received an Australian patent (AU2010326651).
Gencor to distribute Gnosis by Lesaffre’s Landkind Pure Salidroside in the United States
September 11th 2024The ingredient is manufactured by Gnosis by Lesaffre as an alternative to rhodiola extract. Salidroside is the most studied bioactive in rhodiola, to which the extract efficacy is attributed to.
New review from BAPP estimates adulteration of five popular botanicals
September 10th 2024The study focused on the adulteration of black cohosh rhizome, echinacea root or herb, elder berry, ginkgo leaf, and turmeric root/rhizome. The authors reviewed 78 publications with a total of 2995 samples. Of the 2995 samples, 818 were reported to be adulterated or mislabeled.